Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-W C Alffenaar

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|March 4, 2015
Influence of inflammation on voriconazole metabolismM A Encalada Ventura, L F R Span, E R van den Heuvel, et al.
Expert Opinion on Emerging Drugs|February 6, 2016
Emerging drugs and alternative possibilities in the treatment of tuberculosisS Hofman, M M Segers, S Ghimire, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 27, 2024
A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugsM Cevik, A Sturdy, A E Maraolo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 1, 2009
Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MSJ W C Alffenaar, A M A Wessels, K van Hateren, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 11, 2018
Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patientsM A Zuur, A D I van Asselt, N van 't Boveneind-Vrubleuskaya, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|September 11, 2020
Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic reviewR A Chimeh, F Gafar, I S Pradipta, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 24, 2008
Ethambutol-induced optical neuropathy: risk of overdosing in obese subjectsR E Hasenbosch, J W C Alffenaar, S A Koopmans, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2022
Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive CandidiasisJ M Boonstra, K C van der Elst, J G Zijlstra, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2009
Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitisJ W C Alffenaar, R van Altena, H J Bökkerink, et al.
The Journal of Antimicrobial Chemotherapy|July 10, 2014
Five year results of an international proficiency testing programme for measurement of antifungal drug concentrationsV J C Lempers, J W C Alffenaar, D J Touw, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|March 4, 2015
Influence of inflammation on voriconazole metabolismM A Encalada Ventura, L F R Span, E R van den Heuvel, et al.
Expert Opinion on Emerging Drugs|February 6, 2016
Emerging drugs and alternative possibilities in the treatment of tuberculosisS Hofman, M M Segers, S Ghimire, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 27, 2024
A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugsM Cevik, A Sturdy, A E Maraolo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 1, 2009
Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MSJ W C Alffenaar, A M A Wessels, K van Hateren, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 11, 2018
Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patientsM A Zuur, A D I van Asselt, N van 't Boveneind-Vrubleuskaya, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|September 11, 2020
Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic reviewR A Chimeh, F Gafar, I S Pradipta, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 24, 2008
Ethambutol-induced optical neuropathy: risk of overdosing in obese subjectsR E Hasenbosch, J W C Alffenaar, S A Koopmans, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2022
Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive CandidiasisJ M Boonstra, K C van der Elst, J G Zijlstra, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2009
Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitisJ W C Alffenaar, R van Altena, H J Bökkerink, et al.
The Journal of Antimicrobial Chemotherapy|July 10, 2014
Five year results of an international proficiency testing programme for measurement of antifungal drug concentrationsV J C Lempers, J W C Alffenaar, D J Touw, et al.
Pageof 5